Lomitapide’s effects may also extend to hematological malignancies, with recent evidence indicating that targeting PARP14 with lomitapide attenuates drug resistance via DRP1-induced mitophagy activation in multiple myeloma [182]. Here, PARP14 is linked to plasma cell myeloma.